Alice R.T. Bergin

University of Melbourne — Australia

Medicine · Health Sciences

5h-index450citations36works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(19), Cancer Treatment and Pharmacology(19), Advanced Breast Cancer Therapies(15), Global Cancer Incidence and Screening(6), Prostate Cancer Treatment and Research(3)

Publications36 total

Table S2 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
2025Open Access
Data from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
2025Open Access
Figure S1 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
2025Open Access
Table S1 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
2025Open Access
Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Cancer Epidemiology Biomarkers & Prevention·2025Open Access
PP108 A Systematic Review Of Reactogenicity And Safety Of Recombinant Zoster Vaccine For Prevention Of Herpes Zoster In Adults
International Journal of Technology Assessment in Health Care·2024Open Access
Rapid health technology assessment to inform policy: a case study with respiratory syncytial virus
European Journal of Public Health·2024· 2 citedOpen Access
Spatial transcriptomics and the anatomical pathologist: Molecular meets morphology
Histopathology·2023· 26 citedOpen Access
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status
Cancer Immunology Research·2023· 1 cited
Table S7 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Tables S1-5 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Figures S1-8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Table S6 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Table S9 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Figures S1-8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Table S9 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Table S6 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Table S8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Table S8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
Supplementary Methods from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Mark Rosenthal(19), Sheau Wen Lok(18), Jayesh Desai(18), Danny Liew(18), Anand Murugasu(18), Andrew W. Roberts(18), Kylie Shackleton(18), Sarah‐Jane Dawson(18), Jane E. Visvader(18), Geoffrey J. Lindeman(18), François Vaillant(17), Charis E. Teh(17), Louisa L. Lo(17), Antonia N. Policheni(17), Sarah Ftouni(17), Luke C. Gandolfo(17), He K. Liu(17), Kate Moodie(17), Bhupinder Pal(17), Maria João Silva(17)